Could GLP-1 Medicines Affect Alcohol Cravings? The Research Is Early

Some people taking GLP-1 medicines say they think about alcohol less, or that a drink just doesn't appeal the way it used to. Researchers are taking that seriously: GLP-1 signaling affects appetite and may also influence the brain's reward system. Randomized trials are now starting to report results. They're encouraging, but they're still small and early, and as of October 2026 no GLP-1 medicine is approved to treat alcohol use disorder (AUD).

What have randomized trials found?

Here's what the main trials in people with AUD have reported so far:

• Exenatide (2022, Denmark): 127 treatment-seeking adults with AUD received exenatide or placebo for 26 weeks alongside cognitive behavioral therapy. Exenatide did not reduce heavy drinking days overall. An exploratory analysis suggested less drinking in participants with obesity, which helped shape later studies.
• Semaglutide injection (2025, US): 48 adults with AUD who weren't seeking treatment received low-dose semaglutide or placebo for 9 weeks. Semaglutide reduced how much alcohol people drank in a lab session, drinks per drinking day and craving, but not the number of drinking days or average drinks per day.
• Semaglutide 2.4 mg with obesity (Lancet, May 2026, Denmark): 108 treatment-seeking adults with moderate-to-severe AUD and obesity received weekly semaglutide 2.4 mg or placebo for 26 weeks, plus cognitive behavioral therapy. Heavy drinking days fell by about 41 percentage points from baseline with semaglutide versus about 26 with placebo, a difference of about 14 points. Gastrointestinal side effects were more common with semaglutide.
• Oral semaglutide (American Journal of Psychiatry, September 2026): 50 treatment-seeking adults with moderate-to-severe AUD took oral semaglutide or placebo for 8 weeks. It didn't significantly reduce lab-measured craving (the main outcome) or drinks per day, but it did reduce heavy drinking days and everyday craving.

Notice that the placebo groups often improved too, especially when everyone got therapy. That's why comparison groups matter.

Why this isn't settled yet

These trials were small and short, and they used different drugs, doses and populations. Some main outcomes were positive and others weren't. Larger, longer trials are still needed to show who benefits, by how much, for how long, and how well it works in people with AUD who don't have obesity. A 2026 expert review reached a similar conclusion: the signals from animal and human studies line up, but more randomized trials are needed before GLP-1s can be called an established AUD treatment.

What about stories online?

Personal stories can't tell us how common reduced cravings are or whether the medicine caused the change. Observational studies that compare people who did and didn't take a GLP-1 can also be skewed by other differences between those groups. If you've noticed a change, it's worth mentioning to your clinician, but it's not proof for anyone else.

What if alcohol use is a concern now?

Please don't wait for GLP-1 research to mature before asking for help. Effective treatments already exist, including counseling and FDA-approved medicines for AUD, and a healthcare professional can help you choose. In the US, the NIAAA Alcohol Treatment Navigator is a free starting point, and SAMHSA's National Helpline (1-800-662-4357) is free and confidential. Don't start, stop or change a GLP-1 medicine to alter your drinking, and be wary of online sellers offering these drugs for unapproved uses.

Stopping heavy drinking suddenly can cause dangerous withdrawal, so if you drink heavily every day, talk to a clinician before cutting back. If you're curious about how alcohol and GLP-1 medicines interact day to day, see alcohol while taking a GLP-1.

How to read future headlines

Look for the number of participants, whether there was a placebo group, how long the study lasted, what exactly was measured and whether results have been repeated. Check whether people had diagnosed AUD or were a broader group, and whether the drug is approved for that use where you live.

The honest headline right now is "a promising question with growing trial evidence," not "Ozempic cures alcohol addiction."